|Day Low/High||2.40 / 2.44|
|52 Wk Low/High||2.81 / 6.80|
VL-2397 Data to be presented at ASM Microbe 2017 Conference in June
Vical plans to advance the bivalent vaccine to a Phase 2 trial in 2016 and maintains current financial guidance for 2016
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.